Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcellx, Inc. - Common Stock (NQ: ACLX ) 54.41 -1.38 (-2.47%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Arcellx, Inc. - Common Stock < Previous 1 2 3 4 Next > Expert Ratings For Arcellx May 31, 2024 Via Benzinga 7 Biotech Stocks to Put on Your Breakthrough Radar May 27, 2024 Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. Via InvestorPlace Analyst Expectations For Arcellx's Future May 14, 2024 Via Benzinga ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine May 09, 2024 These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. Via InvestorPlace Peering Into Arcellx's Recent Short Interest April 15, 2024 Via Benzinga Arcellx Analysts Boost Their Forecasts After Q4 Results February 29, 2024 Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday. Via Benzinga Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know January 04, 2024 Via Benzinga Where Arcellx Stands With Analysts December 11, 2023 Via Benzinga Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley March 07, 2024 Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. Via Benzinga The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. Via InvestorPlace Decoding Bearish Analog And The Warning Signs You Can't Ignore February 07, 2024 A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. Via Talk Markets Topics Stocks Exposures US Equities Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market January 16, 2024 Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. Via InvestorPlace Exposures Product Safety Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 January 04, 2024 Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... Via Benzinga Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development December 15, 2023 These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. Via InvestorPlace Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 12, 2023 Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. Via Benzinga Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say December 11, 2023 Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or Via Benzinga Chart Of The Day: Arcellx - Reimagining Cell Therapy December 08, 2023 Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Via Talk Markets 3 Biotech Stocks That Could Be Multibaggers in the Making November 30, 2023 Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. Via InvestorPlace Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead November 15, 2023 The companies will work together on treatments for multiple myeloma and lymphomas. Via Investor's Business Daily Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? November 02, 2023 Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra Via Benzinga 7 Biotech Stocks to Get In Now Before Investors Catch On October 23, 2023 Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. Via InvestorPlace Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs October 02, 2023 CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. Via InvestorPlace Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session November 02, 2023 Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. Via Benzinga Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday November 02, 2023 U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential August 15, 2023 The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program. Via Benzinga Exposures Product Safety FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study August 15, 2023 The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 October 17, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session August 14, 2023 Via Benzinga Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 20, 2023 Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.